Korean J Gastroenterol.  2019 Jun;73(6):373-374. 10.4166/kjg.2019.73.6.373.

Genetic Mutation as a Predictive Biomarker for FOLFIRINOX in Patients with Metastatic Pancreatic Adenocarcinoma

• Kim J

• KMID: 2454101
• DOI: http://doi.org/10.4166/kjg.2019.73.6.373

Abstract

No abstract available.

MeSH Terms

Adenocarcinoma*
Humans

Reference

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362:1605–1617.

2. Hruban RH, Goggins M, Kern SE. Molecular genetics and related developments in pancreatic cancer. Curr Opin Gastroenterol. 1999; 15:404–409.

3. Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014; 111:1132–1138.

4. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol. 2012; 30:2654–2663.

5. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364:1817–1825.

6. Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015; 518:495–501.

7. Salo-Mullen EE, O'Reilly EM, Kelsen DP, et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer. 2015; 121:4382–4388.